Protagenic Therapeutics Common Stock

Protagenic Therapeutics posts a common stock of $200 as of December 2025. That compares with $730 in the prior-year period — down 73.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Protagenic Therapeutics's common stock was $730. The latest reading is $200 — a 73.1% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Protagenic Therapeutics's financial statement story. At $200, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PTIX's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Protagenic Therapeutics's other metric pages and overview cover the third.

Judging Protagenic Therapeutics against Industrials peers is usually better than using a market-wide rule of thumb. Business models inside Industrials are more comparable, which makes gaps in common stock easier to interpret. Start with $200 here, then scan peer and history charts to see if the gap is persistent.